We are live on ! Find out more
AG

Aperio Group Portfolio holdings

AUM $33.8B
1-Year Est. Return 31.46%
This Fund
S&P 500
This Quarter Est. Return
+1.96%
1 Year Est. Return
+31.46%
3 Year Est. Return
+70.41%
5 Year Est. Return
+146.02%
10 Year Est. Return
AUM
$25.3B
AUM Growth
+$814M
Cap. Flow
+$613M
Cap. Flow %
2.42%
Top 10 Hldgs %
16.08%
Holding
3,081
New
5
Increased
1,358
Reduced
932
Closed
769

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$31.9M
2
AAPL icon
Apple
AAPL
+$24.9M
3
T icon
AT&T
T
+$21.1M
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$20.2M
5
BIIB icon
Biogen
BIIB
+$19.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$34M
2
RHT
Red Hat Inc
RHT
+$22.2M
3
HSBC icon
HSBC
HSBC
+$20.3M
4
APC
Anadarko Petroleum
APC
+$19.9M
5
CAJ
Canon, Inc.
CAJ
+$16.2M

Sector Composition

Rank Sector Weight
1 Technology 19.05%
2 Financials 16.76%
3 Healthcare 12.56%
4 Consumer Discretionary 10.05%
5 Communication Services 8.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FNSR
3076
DELISTED
Finisar Corp
FNSR
-20,704
Closed -$474K
PRMW
3077
DELISTED
Primo Water Corporation
PRMW
-2,832
Closed -$35K
LJPC
3078
DELISTED
La Jolla Pharmaceutical Company
LJPC
-1,726
Closed -$16K
BHVN
3079
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
-1,617
Closed -$71K
FDC
3080
DELISTED
First Data Corporation
FDC
-76,404
Closed -$2.07M
TCF
3081
DELISTED
TCF Financial Corporation
TCF
-60,015
Closed -$1.25M

Similar funds

Aperio Group's Q3 2019 Portfolio in Review

As of Q3 2019, Aperio Group held 3,081 positions worth $25.3B, up 3.3% from $24.5B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Aperio Group's Q3 2019 filing shows 5 new, 1,358 increased, 932 reduced and 769 closed positions. Its largest new stake was Genmab: 211,272 shares worth $4.28M. The largest sale was Pfizer, an estimated $34M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.

  • Aperio Group's largest Q3 2019 buy was Genmab: 211,272 shares worth $4.28M.
  • Aperio Group added most to Microsoft in Q3 2019, an estimated $31.9M increase.
  • Aperio Group's biggest Q3 2019 reduction was Pfizer, cutting an estimated $34M.
  • Aperio Group fully exited Red Hat Inc in Q3 2019, selling an estimated $22.2M.
  • Aperio Group's ten largest holdings make up 16% of its $25.3B portfolio in Q3 2019.
  • Aperio Group opened 5 new positions and closed 769 in Q3 2019.
  • Aperio Group's portfolio value rose 3.3% quarter-over-quarter to $25.3B.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.